Recent genomic analyses of human cancer have identified that the cohesin genes, and STAG2 in particular, are frequent targets of mutational inactivation in a select subset of tumor types that include glioblastoma, urothelial carcinoma, Ewing sarcoma, and myeloid leukemia24–29. This evidence concerns the gene STAG2 and glioblastoma.